

Randomized Controlled Hydroxychloroquine Trials With Negative Outcomes:

- Borba, et al. (Brazil) – **RCT. Double Blinded. Hospitalized with severe COVID-19.** 18.9% of the patients in the high dose group developed QTc interval abnormalities compared to 11.1% in the low dosage group. The lethality in the high dose group was more than twice that of the low dose control. The study was discontinued. April 24, 2020. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765270>
- Boulware, et al. (USA) – **RCT. Double Blinded.** Prophylaxis post exposure to SARS-CoV-2 “After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as **postexposure prophylaxis within 4 days** after exposure.” New England Journal of Medicine. June 3, 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2016638>
- Oxford RECOVERY Study: (UK) – **RCT. Hospitalized Patients.** “There was no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes.” The Trial was halted because of lack of efficacy. June 5, 2020. <https://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19>
- Skipper, et al. (USA & Canada) – **RCT. Double Blind. Non-Hospitalized Patients.** “Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.” Annals of Internal Medicine. July 16, 2020. <https://www.acpjournals.org/doi/10.7326/M20-4207>
- Cavalcanti, et al. (Brazil) – **RCT. Hospitalized Patients.** “Among patients **hospitalized with mild-to-moderate Covid-19**, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.” New England Journal of Medicine. July 23, 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2019014>
- Abella, et al. (USA) -- **RCT. Double Blind.** Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. **Prophylaxis.** Benefit not demonstrated. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265>
- WHO SOLIDARITY Trail, Pan, et. al. (WHO). **RCT. Adult Hospitalized Patients.** Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. Benefit not demonstrated. <https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1>
- Rajasingham, et al. (United States) – **RCT. Double Blind. Prophylaxis** of Healthcare Workers. Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratory-confirmed Covid-19 or Covid-19-compatible illness among healthcare workers. <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1571/5929230>
- Self, et al (United States) --- **RCT. Double Blind. Adult Hospitalized Patients** with Respiratory Illness. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. ...did not significantly improve clinical status at day 14. <https://jamanetwork.com/journals/jama/fullarticle/2772922>